Please assess the completion status of the following clinical trial:

Trial Title: Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with autosomal dominant polycystic kidney disease (ADPKD) aged 18-55~* estimate glomerular filtration rate (GFR) at or above ≥ 50 ml/min/1.73 m2 by any GFR formula~* Normal liver enzymes (ALT/AST)~* fasting blood glucose between 70 and120~* for female patients, a willingness to use double contraception to avoid pregnancy while in study~* able to give informed consent~* In the opinion of the investigator, high likelihood of progressive kidney disease~Exclusion Criteria:~* diabetes, defined as any of the following: fasting blood sugar \> 130 times two, HgbA1C \> 7, on any blood sugar lowering medication, or past diagnosis of diabetes not occurring during pregnancy~* uncontrolled hypertension as determined by the examining physician~* history of impaired systolic function (ejection fraction \< 50%) by previous echocardiogram or known ischemic cardiovascular disease~* findings suggestive of a kidney disease other than ADPKD~* systemic illness requiring immunosuppressive or anti-inflammatory agents~* congenital absence of a kidney or history of a total nephrectomy~* history of cyst reduction or partial nephrectomy~* history of renal cyst aspiration within the previous year~* History of bladder cancer, or gross hematuria~* inability to undergo MRI due to implantable devices or foreign objects that preclude MRI~* active renal transplant~* allergy or sensitivity to any of the components of the test materials~* institutionalized~* currently pregnant or plans to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subject will be on placebo
- Pioglitazone Arm (Type: ACTIVE_COMPARATOR): Subject will be on pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).